Healthcare player Zydus Cadila (Cadila Healthcare Limited) on Wednesday announced that the company has received the tentative approval from the US Drug Regulator, USFDA to market its Clofarabine Injection 20mg/20ml vials.
The company's share prices gained 3 per cent to trade at Rs 345.80 on the Bombay Stock Exchange in pre-close trade.
The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in financial year 2003-04, the company statement said.